Elite Pharmaceuticals Inc (ELTP)

[Couch]

Chris Dick - Elite Pharmaceuticals, Inc. - COO and President
Well, I think our strategy, Anthony, is around doing an ANDA or 505(b)(2) that we can control ourselves. And we think -- which is what I was talking about earlier about doing bioequivalent studies and those types of studies -- to get a product on the market with the abuse resistant technology.
We think if we think if we can do that type of thing, then the value for the -- a product that would require a full efficacy study will go up, and we'll do it in that kind of timeframe. So strategically we're kind of looking at it as a two-step process. Do these first and then do a bigger strategic alliance on a more costly study.

Jerry Treppel - Elite Pharmaceuticals, Inc. - Chairman and CEO
Full disclosure here. There's no question that the issuance of that patent has piqued the industry's interest. Okay? And we know that from the calls
that we get.
But, as I said before, piquing interest is not the same thing as I want to sit down and discuss terms with you. And we think in order for that to happen, as Chris just said, you have got to demonstrate to people that I can commercially make -- scale it up; I've done the biostudies; I have a product. Okay? And that's our goal, and we will get there in this fiscal year.